What is NDC 0143-9144?

0143-9144 is the product NDC for Liraglutide, Liraglutide 6 mg/mL injection, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Liraglutide?

14 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Liraglutide NDC 0143-9144 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0143-9144Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00143-9144Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0143-9144-02	0014391440200143914402	2 SYRINGE, PLASTIC in 1 CARTON (0143-9144-02) / 3 mL in 1 SYRINGE, PLASTIC (0143-9144-01)Marketed from Dec 24, 2024
0143-9144-03	0014391440300143914403	3 SYRINGE, PLASTIC in 1 CARTON (0143-9144-03) / 3 mL in 1 SYRINGE, PLASTIC (0143-9144-01)Marketed from Dec 24, 2024

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Liraglutide
Generic name (nonproprietary): liraglutide
Active ingredients: Liraglutide — 6 mg/mL
Dosage form: Injection
Route: Subcutaneous
Labeler: Hikma Pharmaceuticals USA Inc.NDC labeler code 0143
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 215503
Marketing start: Dec 24, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
Identifiers: Product ID 0143-9144_4e2acb7a-d32d-49d3-b59b-39332b5809f3SPL ID 4e2acb7a-d32d-49d3-b59b-39332b5809f3SPL set ID 2100ec49-57b2-4330-ab5f-057ce9b7e4d0RxCUI 897122UNII 839I73S42A
Pharmacologic class: GLP-1 Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400143914402 followed by a unit qualifier and the quantity

Package 00143-9144-02. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 14, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Liraglutide injection is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus Limitations of Use : Liraglutide injection contains liraglutide. Coadministration with other liraglutide-containing products is not recommended. Liraglutide injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Limitations of Use : Coadministration with other liraglutide-containing products is not recommended.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0143-9144

What is NDC 0143-9144?: 0143-9144 is the product NDC for Liraglutide, Liraglutide 6 mg/mL injection, listed with the FDA by Hikma Pharmaceuticals USA Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Liraglutide.
What is the active ingredient?: Liraglutide.
Who is the labeler?: Hikma Pharmaceuticals USA Inc., NDC labeler code 0143. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Liraglutide?: 14 other product NDCs are listed under this name. See all Liraglutide NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Liraglutide NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Biocon Pharma Inc.	70377-094	70377-0094-5270377-0094-53
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Biocon Pharma Inc.	70377-095	70377-0095-5270377-0095-53
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	NorthStar Rx LLC	72603-745	72603-0745-0272603-0745-03
liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Orbicular Pharmaceutical Technologies Private Limited	81607-019	81607-0019-0181607-0019-02
liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Cipla USA Inc.	69097-910	69097-0910-5569097-0910-68
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	A-S Medication Solutions	50090-8145	50090-8145-00
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Cipla USA Inc.	69097-920	69097-0920-6769097-0920-68
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Orbicular Pharmaceutical Technologies Private Limited	81607-018	81607-0018-0181607-0018-02
Liraglutide	Liraglutide 6 mg/mL	InjectionSubcutaneous	Lupin Pharmaceuticals, Inc.	70748-346	70748-0346-0270748-0346-03
Liraglutide	Liraglutide 6 mg/mL	Injection, SolutionSubcutaneous	Teva Pharmaceuticals, Inc.	0480-7250	00480-7250-46

All 15 Liraglutide NDCs

Other NDCs under ANDA 215503

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 215503
Product	Strength	Form · route	Labeler	Product NDC
Liraglutide	Liraglutide 18 mg/3mL	Injection, SolutionSubcutaneous	Hybio Pharmaceutical Co., Ltd. (Pingshan Factory)	14403-3400